A Craig Lockhart
Overview
Explore the profile of A Craig Lockhart including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
94
Citations
3884
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang J, Xiu J, Battaglin F, Arai H, Soni S, Zhang W, et al.
NPJ Precis Oncol
. 2024 Sep;
8(1):214.
PMID: 39349771
Although histological and molecular classifications have been extensively studied for gastric cancer (GC), targeted therapies for GC remain limited. CDH1 mutations (MT) are characteristic of genomically stable GC and are...
2.
Zeng Y, Lockhart A, Jin R
Expert Opin Drug Discov
. 2024 Jun;
19(8):873-886.
PMID: 38919123
Introduction: Gastric cancer remains a formidable challenge in oncology with high mortality rates and few advancements in treatment. Claudin-18.2 (CLDN18.2) is a tight junction protein primarily expressed in the stomach...
3.
Philip P, Azar I, Xiu J, Hall M, Hendifar A, Lou E, et al.
Clin Cancer Res
. 2022 Mar;
28(12):2704-2714.
PMID: 35302596
Purpose: KRAS mutation (MT) is a major oncogenic driver in pancreatic ductal adenocarcinoma (PDAC). A small subset of PDACs harbor KRAS wild-type (WT). We aim to characterize the molecular profiles...
4.
Hyman D, Tran B, Paz-Ares L, Machiels J, Schellens J, Bedard P, et al.
JCO Precis Oncol
. 2022 Feb;
3:1-13.
PMID: 35100734
Purpose: Concurrent PIK3CA mutations and fibroblast growth factor receptor (FGFR) alterations occur in multiple cancer types, including estrogen receptor-positive breast cancer, bladder cancer, and endometrial cancer. In this first-in-human combination...
5.
Lee S, Wages N, Goodman K, Lockhart A
JCO Precis Oncol
. 2022 Jan;
5:937-938.
PMID: 34994621
No abstract available.
6.
Vlacich G, Ballard A, Badiyan S, Spraker M, Henke L, Kim H, et al.
Clin Transl Radiat Oncol
. 2021 Jul;
30:19-25.
PMID: 34278011
Background And Purpose: Radiation dose escalation to improve poor outcomes with chemoradiation in locally advanced esophageal carcinoma is limited in part by increased toxicity. This Phase I study investigates the...
7.
Wang J, Xiu J, Baca Y, Battaglin F, Arai H, Kawanishi N, et al.
Oncogene
. 2021 Jun;
40(30):4894-4905.
PMID: 34163031
Frequent mutations of genes in the histone-lysine N-methyltransferase 2 (KMT2) family members were identified in gastric cancers (GCs). Understanding how gene mutations of KMT2 family affect cancer progression and tumor...
8.
Lee S, Wages N, Goodman K, Lockhart A
JCO Precis Oncol
. 2021 Jun;
5:317-324.
PMID: 34151131
In recent years, the landscape in clinical trial development has changed to involve many molecularly targeted agents, immunotherapies, or radiotherapy, as a single agent or in combination. Given their different...
9.
Pedersen K, Grierson P, Picus J, Lockhart A, Roth B, Liu J, et al.
Invest New Drugs
. 2021 Mar;
39(5):1298-1305.
PMID: 33738668
Background Anti-vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI) combined with mTOR inhibitors, like everolimus, result in significant responses and prolonged progression-free survival (PFS) among patients with renal...
10.
Park H, Williams K, Trikalinos N, Larson S, Tan B, Waqar S, et al.
Cancer Chemother Pharmacol
. 2020 Nov;
87(3):337-347.
PMID: 33159216
Purpose: Resistance to treatment with inhibitors of mammalian target of rapamycin (mTOR) is partially mediated by activation of epidermal growth factor receptor (EGFR). We conducted a phase I study to...